Equities Analysts Offer Predictions for NTLA FY2025 Earnings

Intellia Therapeutics, Inc. (NASDAQ:NTLA) – Research analysts at Cantor Fitzgerald issued their FY2025 earnings per share estimates for Intellia Therapeutics in a report issued on Monday, March 17th. Cantor Fitzgerald analyst R. Bienkowski anticipates that the company will post earnings per share of ($4.34) for the year. The consensus estimate for Intellia Therapeutics’ current full-year earnings is ($5.07) per share.

NTLA has been the subject of a number of other reports. Canaccord Genuity Group restated a “buy” rating and issued a $90.00 price objective on shares of Intellia Therapeutics in a report on Tuesday, November 19th. Wells Fargo & Company lowered their price objective on shares of Intellia Therapeutics from $60.00 to $50.00 and set an “overweight” rating on the stock in a report on Friday, February 28th. Morgan Stanley downgraded shares of Intellia Therapeutics from an “overweight” rating to an “equal weight” rating and lowered their target price for the company from $56.00 to $11.00 in a report on Monday, January 27th. HC Wainwright assumed coverage on shares of Intellia Therapeutics in a report on Wednesday, March 5th. They issued a “buy” rating and a $30.00 target price for the company. Finally, BMO Capital Markets lowered their target price on shares of Intellia Therapeutics from $70.00 to $50.00 and set an “outperform” rating for the company in a report on Friday, January 10th. Two analysts have rated the stock with a sell rating, six have assigned a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $37.56.

Intellia Therapeutics Trading Down 4.1 %

Shares of NTLA stock opened at $9.19 on Wednesday. Intellia Therapeutics has a 1 year low of $8.30 and a 1 year high of $28.54. The stock has a market cap of $951.32 million, a P/E ratio of -1.69 and a beta of 1.97. The stock has a 50 day simple moving average of $10.23 and a 200 day simple moving average of $14.40.

Institutional Investors Weigh In On Intellia Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the stock. California State Teachers Retirement System raised its stake in shares of Intellia Therapeutics by 4.1% during the fourth quarter. California State Teachers Retirement System now owns 90,638 shares of the company’s stock worth $1,057,000 after acquiring an additional 3,596 shares in the last quarter. Polar Asset Management Partners Inc. grew its holdings in shares of Intellia Therapeutics by 1,144.1% in the fourth quarter. Polar Asset Management Partners Inc. now owns 282,400 shares of the company’s stock worth $3,293,000 after purchasing an additional 259,700 shares during the last quarter. GF Fund Management CO. LTD. bought a new position in shares of Intellia Therapeutics in the fourth quarter worth approximately $25,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its holdings in shares of Intellia Therapeutics by 5.0% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 483,185 shares of the company’s stock worth $5,634,000 after purchasing an additional 23,173 shares during the last quarter. Finally, Voloridge Investment Management LLC grew its holdings in shares of Intellia Therapeutics by 226.8% in the fourth quarter. Voloridge Investment Management LLC now owns 1,526,994 shares of the company’s stock worth $17,805,000 after purchasing an additional 1,059,751 shares during the last quarter. 88.77% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Intellia Therapeutics

In other news, CEO John M. Leonard sold 26,807 shares of the stock in a transaction dated Friday, January 3rd. The shares were sold at an average price of $12.18, for a total value of $326,509.26. Following the sale, the chief executive officer now directly owns 941,115 shares of the company’s stock, valued at approximately $11,462,780.70. This represents a 2.77 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Over the last ninety days, insiders have sold 29,000 shares of company stock valued at $352,551. 3.20% of the stock is currently owned by corporate insiders.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.